# pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

> **NCT06253507** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (estimated)

## Conditions studied

- p47
- Autosomal Recessive
- Chronic Granulomatous Disease

## Interventions

- **BIOLOGICAL:** Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47

## Key facts

- **NCT ID:** NCT06253507
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-06-25
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253507, "pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06253507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*